riverhills neuroscience logo

Clinical Research

Clinical Research

About Clinical Research

Clinical research enables patients with chronic neurological diseases to try leading-edge treatments before they’re available to the public. At Riverhills Neuroscience, with three Cincinnati, Ohio, area offices in Norwood, Westside, and Anderson, as well as an office in Crestview Hills, Kentucky, the region’s top neurology specialists offer research opportunities to patients with Multiple Sclerosis, Parkinson’s Disease, and other neurological diseases. You can be part of future treatments by participating in clinical research studies. To learn more, call the office nearest you or click the online contact feature now.

Clinical Research Q&A

What are clinical research studies?

Clinical research studies evaluate the newest potential treatments before they’re available to the general public. Patients who volunteer as participants typically receive the treatment in question free of charge in exchange for information about the effects of the treatment. 

By joining a clinical research study, you can help further medical knowledge about your disease and can contribute to helping other people get the help they need in the future.

At Riverhills Neuroscience, studies are conducted by eminently qualified, certified clinical research professionals. 

If you participate in a clinical research study, you’ll come to the office for regularly-scheduled appointments for the duration of the trial, which can last from a few months to years. 

What diseases do clinical research studies cover?

As a multidisciplinary neurology practice, Riverhills Neuroscience conducts ongoing research to improve the quality of care available to patients living with neurological diseases. The practice has conducted research studies related to:

  • Alzheimer’s disease
  • Parkinson’s disease
  • Epilepsy
  • Multiple sclerosis
  • Advanced surgical implants
  • Advanced surgical instrumentation

While many innovative and highly effective treatments are available for patients today, Riverhills Neuroscience is committed to continually seeking newer and more effective options until true cures are found.  

How can I qualify for clinical research studies?

Every clinical research study has its own unique requirements, which may include:

Age

Most clinical studies have specific age ranges, such as 40-80.

Sex

Clinical studies may accept only male or female participants. 

Medication 

The medications you currently take can qualify or exclude you from a clinical study, as the study drug may interact with other medications.

Treatment history

Your treatment history, including past surgeries, may qualify or disqualify you from a research study. For example, a study for a Parkinson’s disease drug might exclude patients who previously had a deep brain stimulation procedure. 

Clinical research studies may also have other requirements. Riverhills Neuroscience is happy to help patients enroll in clinical research studies. 

What clinical research studies are enrolling now?

Riverhills Neuroscience offers new clinical research participation opportunities to qualifying patients regularly. Clinical research studies have a limited enrollment period, so the opportunities change over time.

To learn more about current opportunities, call the office or complete a "contact us" form.

 

MULTIPLE SCLEROSIS ACTIVELY ENROLLING STUDIES

SAR441344/FREXALIMAB

A Phase 3, randomized, double-blind, 2-arm, placebo-controlled, parallel group, multicenter, event-driven (6-month cCDP) trial with a variable treatment duration ranging from approximately 27 to 51 months in participants with nrSPMS.

Purpose: To assess for the efficacy and safety of SAR441344 in adults with nonrelapsing secondary progressive multiple sclerosis.

 

SAR442168/PERSEUS

*CLOSING FOR ENROLLMENT 6/30/2024*  

A Phase 3, randomized double-blind, 2-arm, placebo-controlled, parallel-group, multicenter, event-driven (3M-cCDP) trial in participants with PPMS with a variable treatment duration ranging from approximately 12 to 60 months.

Purpose: To determine the efficacy of SAR442168 “tolebrutinib” compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS).